Statins and prevention of strokes;Statines et prévention des accidents vasculaires cérébraux

Revue Neurologique

Volumn 161, Issue 2, 2005, Pages 237-244

  Neau, J P ^a   Moumy, H ^a   Mathis, S ^a   Gil, R ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Pathophysiological mechanisms; Perspectives; Primary and secondary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ATHEROGENESIS; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDICATION; FRANCE; HUMAN; INFLAMMATION; PRESCRIPTION; PUBLICATION; REVIEW; STROKE;

EID: 14644401781     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85031-3     Document Type: Review

References (46)

1. ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM FOR THE PRINCE INVESTIGATORS. (2001). Effect of statin therapy on C-reactiv protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE). A randomized trial and cohort study. JAMA, 286: 64-70.
2. ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP. (2002). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA, 288: 2998-3007.
3. ATKINS D, PSATY BM, KOEPSELL TD, LONGSTRETH WT JR, LARSON EB. (1993). Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med, 119: 136-145.
4. BYINGTON RP, JUKEMA JW, SALONEN JT et al. (1995). Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation, 92: 2419-2425.
5. CASTELLI WP, ANDERSON K, WILSON PW, LEVY D. (1992). Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol, 2: 23-28.
6. COLLINS R, ARMITAGE J, PARISH S, SLEIGHT P, PETO R, HEART PROTECTION STUDY COLLABORATIVE GROUP. (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 363: 757-767.
7. CROUSE JR IIIRD, BYINGTON RP, BOND MG et al. (1995). Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol, 75: 455-459.
8. DANGAS G, SMITH DA, UNGER AH et al. (2000). Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Throm Haemost, 83: 688-692.
9. DELANTY N, VAUGHAN CJ. (1997). Vascular effects of statins in stroke. Stroke, 28: 2315-2320.
10. DEMCHUK AM, HESS DC, BRASS LM, YATSU FM. (1999). Is cholesterol a risk factor for Stroke? Yes. Arch Neurol, 56: 1518-1520.
11. ENDRES M, LAUFS U, HUANG Z, NAKAMURA T, HUANG P, MOSKOWITZ MA, LIAO JK. (1998). Stroke protection by 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase inhibitors mediated by endothelial nitric oxide synthetase. Proc Natl Acad Sci USA, 95: 8880-8885.
12. FURBERG CD, ADAMS HP JR, APPLEGATE WB et al. (1994). Effects of lovastatin on early carotid atherosclerosis and cardiovascular effects. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation, 90: 1679-1687.
13. HACHINSKI V, GRAFFAGNINO C, BEAUDRY M et al. (1996). Lipids and stroke: a paradox resolved. Arch Neurol, 53: 303-308.
14. HANKEY GJ, WARLOW C. (1999). Treatment and secondary prevention of stroke: evidence, costs and effects on individuals and population. Lancet, 354: 1457-1463.
15. HEART PROTECTION STUDY COLLABORATIVE GROUP. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360: 7-22.
16. HEART PROTECTION STUDY COLLABORATIVE GROUP. (2003). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 361: 2005-2016.
17. ISO H, JACOBS DR JR, WENTWORTH D, NEATON JD, COHEN JD. (1989). Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N Engl J Med, 320: 904-910.
18. JONES J, KAFONEK S, LAURORA I, HUNNIN-GHAKE D FOR THE CURVES INVESTIGATORS. (1998). Comparative dose efficacy study of Atorvastatine versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin, in patients with hypercholesterolemia. Am J Cardiol, 81: 582-587.
19. KASTE M. (2003). Statins in threatened stroke. Stroke, 34: 351-353.
20. KOREN-MORAG N, TANNE D, GRAFF E, GOLDBOURT U. (2002). Low-and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med, 162: 993-999.
21. LANDAU WM. (1999). Is cholesterol a risk factor for stroke? No. Arch Neurol, 56: 1521-1524.
22. LAROSA JC, HUNNINGHAKE D, BUSH D et al. (1990). The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation, 81: 1721-1733.
23. LINDENSTROM E, BOYSEN G, NYBOE J. (1994). Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ, 309: 11-15.
24. NEATON JD, BLACKBURN H, JACOBS D et al. (1992). Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med, 152: 1490-1500.
25. PROSPECTIVE STUDIES COLLABORATION. (1995). Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet, 346: 1647-1653.
26. QIZILBASH N, DUFFY SW, WARLOW C, MANN J. (1992). Lipids are risk factors for ischaemic stroke. Overview and review. Cerebrovasc Dis, 2: 127-136.
27. RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNWALD E FOR THE CHOLESTEROL AND RECURRENT EVENTS (CARE) INVESTIGATORS. (1999). Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100: 230-235.
28. RIDKER PM, RIFAI N, CLEARFIELD M, DOWNS JR, WEIS SE, MILES JS, GOTTO AM FOR THE AIRFORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY INVESTIGATORS. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Eng J Med, 344: 1959-1965.
29. RUBINS HB, ROBINS SJ, COLLINS D et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med, 341: 410-418.
30. RUBINS HB, ROBINS SJ, COLLINS D et al. (2002). Diabetes, Plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of veterans Affairs. High-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 162: 2597-2604.
31. SACCO RL, BENSON RT, KARGMAN DE et al. (2001). High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA, 285: 2729-2735.
32. SACKS FM, PFEFFER MA, MOYE LA et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 335: 1001-1009.
33. SALONEN R, NYYSSONEN K, PORKKALA E, RUMMUKAINEN J, BELDER R, PARK JS, SALONEN JT. (1995). Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation, 92: 1758-1764.
34. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344: 1383-1389.
35. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al. FOR THE MYOCARDIAL ISCHEMIA REDUCTION WITH AGGRESSIVE CHOLESTEROL LOWERING (MIRACL) STUDY INVESTIGATORS. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 285: 1711-1718.
36. SEVER PS, DALHÖF B, POULTER NR et al. FOR THE ASCOT INVESTIGATORS. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering Ann (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361: 1149-1158.
37. SHEPHERD J, COBBE SM, FORD I et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 333: 1301-1307.
38. SHEPHERD J, BLAUW GJ, MURPHY MB et al. FOR PROSPER STUDY GROUP. PROspective Study of Pravastatin in the Elderly at Risk. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360: 1623-1630.
39. STERZER P, MEINTZSCHEL F, RÖSLER A, LANFEMANN H, STEINMETZ H, SITZER M. (2001). Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke, 32: 2817-2820.
40. SPARCL INVESTIGATORS. (2003). Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovascul Dis, 16: 389-395.
41. TAYLOR AJ, KENT SM, FLAHERTY PJ, COYLE LC, MARKWOOD TT, VERNALIS MN. (2002). "ARBITER": Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A randomised trial comparing the effects of atorvastatin and pravastatin on carotid intima media thickness. Circulation, 106: 2055-2060.
42. UNDAS A, BRUMMEL KE, MUSIAL J, MANN KG, SZCZEKLIK A. (2001). Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V and factor XII and by enhancing factor V inactivation. Circulation, 103: 2248-2253.
43. VAUGHAN CJ, DELANTY N. (1999). Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke, 30: 1969-1973.
44. VERSCHUREN WM, JACOBS DR, BLOEMBERG BP et al. (1995). Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA, 274: 131-136.
45. WHITE HD, SIMES RJ, ANDERSON NE et al. (2000). Pravastatin therapy and the risk of stroke. N Engl J Med, 343: 317-326.
46. YANO K, REED DM, MACLEAN CJ. (1989). Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke, 20: 1460-1465.